Alnylam PharmaceuticalsALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
77% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 60
26% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 168
17% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]
14% more capital invested
Capital invested by funds: $29.8B [Q2] → $34B (+$4.25B) [Q3]
12% more call options, than puts
Call options by funds: $364M | Put options by funds: $325M
8% more funds holding
Funds holding: 515 [Q2] → 554 (+39) [Q3]
0.48% less ownership
Funds ownership: 96.81% [Q2] → 96.34% (-0.48%) [Q3]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
HC Wainwright & Co. Patrick Trucchio 27% 1-year accuracy 42 / 156 met price target | 62%upside $400 | Buy Reiterated | 13 Jan 2025 |
Needham Joseph Stringer 24% 1-year accuracy 31 / 128 met price target | 30%upside $320 | Buy Reiterated | 13 Jan 2025 |
Bernstein William Pickering 14% 1-year accuracy 1 / 7 met price target | 26%upside $310 | Outperform Maintained | 7 Jan 2025 |
Piper Sandler Edward Tenthoff 18% 1-year accuracy 8 / 45 met price target | 20%upside $296 | Overweight Reiterated | 18 Nov 2024 |
Raymond James Gary Nachman 38% 1-year accuracy 5 / 13 met price target | 21%upside $298 | Outperform Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 5 articles about ALNY published over the past 30 days
